



## Noxopharm enhances 2024 cash position via R&D rebate

### Highlights

- Funds received from Australian Government Research and Development Tax Incentive scheme strengthen cash position
- Support for cancer and inflammation drugs, plus upcoming clinical trial

**Sydney, 12 November 2024:** Innovative biotech company **Noxopharm Limited (ASX:NOX)** has received a \$2,342,934.75 rebate under the Australian Government’s Research and Development Tax Incentive scheme for expenditure during FY 2024.

Of the total received, Noxopharm has repaid \$1,873,421 million in principal and interest to Endpoints Capital Pty Ltd, a specialist in life sciences R&D finance, for a secured loan taken out in early September 2024.

Noxopharm CEO Dr Gisela Mautner said: “This year’s R&D rebate helps strengthen our cash position as we continue to advance our Chroma™ and Sofra™ technology platforms while preparing for the upcoming HERACLES clinical trial.

“The Federal R&D rebate is a very welcome initiative that makes a tangible contribution to Australian industry and the development of new assets and intellectual property.”

**-ENDS-**

### About Noxopharm

Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance mRNA vaccines.

The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Chroma™ (oncology) and Sofra™ (inflammation, autoimmunity, and mRNA vaccine enhancement).

Noxopharm also has a major shareholding in US registered, Australia based Nyrada Inc (ASX:NYR), a drug discovery and development company specialising in novel small molecule therapies.

To learn more, please visit: [noxopharm.com](https://noxopharm.com)

#### Investor, Corporate & Media enquiries:

Julian Elliott

M: 0425 840 071

E: [julian.elliott@noxopharm.com](mailto:julian.elliott@noxopharm.com)

#### Company Secretary:

David Franks

T: +61 2 8072 1400

E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)



*Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.*

---

### **Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.